Dr Salani
Module 1: First-Line Therapy for Advanced or Recurrent EC
Eskander R et al. Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial. SGO 2024;Abstract LBA.
Eskander RN et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023;388(23):2159-70. Abstract
Levine DA, The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013 2;497(7447):67-73. Abstract
Mirza MR et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 2023;388(23):2145-58. Abstract
Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42(3):283-99. Abstract
Westin SN et al. Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial. ESMO 2023;Abstract LBA41.
Module 2: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC
Lorusso D et al. Health-related quality of life in patients with advanced endometrial cancer treated with lenvatinib plus pembrolizumab or treatment of physician's choice. Eur J Cancer 2023;186:172-84. Abstract
Makker V et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. J Clin Oncol 2023;41(16):2904-10. Abstract
Makker V et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437-48. Abstract
Makker V et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab.Oncologist 2021;26(9):e1599-608. Abstract
Marth C et al. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. J Clin Oncol 2025;43(9):1083-100. Abstract
Marth C et al. Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase 3 ENGOT-en9/LEAP-001 study. ESGO 2024;Abstract 88.
Ms Lyle
Module 1: First-Line Therapy for Advanced or Recurrent EC
Martins F et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16(9):563-80. Abstract
Dr Slomovitz
Module 3: Novel Investigational Strategies for Newly Diagnosed Advanced EC
Makker V et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol 2024;185:202-11. Abstract
Mirza M et al. Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. SGO 2024;Abstract LBA.
Mirza MR et al. Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial. ESMO Gynecological Cancers Congress 2024;Abstract 38MO.
O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015;60(4):547-60. Abstract
Slomovitz BM et al. Long-term follow up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study. 2023 ASCO Monthly Plenary Series;Abstract 427956.
Vergote I et al. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J Clin Oncol 2023;41(35):5400-10. Abstract
Vikas P et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol 2020;10:570. Abstract
Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42:283-99. Abstract
Module 4: Incidence and Management of HER2-Positive EC
Fu Z et al. Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduct Target Ther 2022;7(1):93. Abstract
Hasegawa K et al. Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial. ESMO 2021;Abstract 813P.
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract
Nishikawa T et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial. J Clin Oncol 2023;41(15):2789-99. Abstract
Ms Shaver
Module 3: Novel Investigational Strategies for Newly Diagnosed Advanced EC
Vergote I et al. ENGOT-EN20/GOG-3083/XPORT-EC-042 - a phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: Rationale, methods, and trial design. Int J Gynecol Cancer 2024;34(8):1283-9. Abstract